Peptides are rapidly emerging as one of the most complex and contested topics in healthcare today, spanning cutting-edge oncology, metabolic disease, and an expanding grey zone of consumer-led experimentation.
For communications leaders in pharma and biotech, this creates a dual challenge:
– navigating a conversation split between scientific credibility and consumer hype
– and identifying which voices actually shape perception, policy, and adoption
To understand how this debate is unfolding, Commetric’s healthcare team analysed global English-language peptide-related conversations on X between January and mid-April 2026, not just to measure buzz and hype, but to uncover who drives the conversation, how narratives form, and where influence truly sits.
Out of 137K X posts on peptides in the context of health, science or fitness since the beginning of the year, sourced via leading social listening platform Meltwater, we narrowed down a corpus of 18K original, quote tweet or reply posts by accounts classified as human, and having at least 600 followers.
As visible from the trend chart, the overall focused peptides conversation, the posts by accounts classified as human, and the posts by accounts ultimately ranked in our Top 100 influencers all displayed an upwards trend, showing more intense conversations on peptides in the context of science, health, and fitness from the end of February onwards.
The watermark moment is unsurprisingly the highly popular guest appearance of U.S. Secretary of Health Robert F. Kennedy Jr. on The Joe Rogan Experience podcast in the week of February 23, where he openly described himself as “a big fan of peptides” citing personal use and positive recovery outcomes. Kennedy criticized the Biden administration’s reclassification of 19 compounded peptides as lacking a safety basis and argued that the move “completely replaced the legal market” with a substandard black market, expressing his intention to restore access through regulated, ethical suppliers.
Beyond listening: how network analysis supports strategic research
Traditional social listening tells you what is being said. Network analysis reveals who matters and how ideas spread.
We mapped in a network all 7,044 accounts sourced from the sample of human-classified accounts above the followers threshold, and ranked the users using our influence network mapping and impact score methodologies to identify the top 100 authentic influencers shaping the conversation.
Using a blend of proprietary AI models and analyst-led enrichment, we:
– Classified stakeholders based on professional identity (e.g. clinicians, academics, biohackers, coaches)
– Identified sub-themes across clinical, performance, longevity, and risk narratives
– Filtered out inauthentic and bot-like behaviour to isolate genuine influence
– Mapped the conversation network to understand how stakeholders connect and amplify each other
The result is a dataset designed not just for reporting – but for decision-making.
Who actually influences the conversation?
To move beyond surface-level metrics, we applied a composite Conversation Impact Score, combining:
– activity (posting volume)
– reach (follower base)
– resonance (engagement)
– consistency (sustained participation)
– network influence (centrality in the conversation network)
This last dimension is critical and is the component in the conversation impact score that carries the biggest weight. Because influence is not just about audience size: it’s about how information flows through the network.
In the peptide debate, this exposes a key insight: The most visible voices are not always the most influential – and the most influential are often those connecting otherwise disconnected communities.
VIEW INTERACTIVE MAP
See the Top 20 influencers on peptides in science, health and fitness below, or download the full Top 100 list here.
Two parallel realities
At a macro level, the peptide conversation splits into two distinct and largely disconnected worlds: science-backed conversation and consumer-led experimentation.
Three thirds, or 66% of the Top 100 influencers are experts – either Experts with academic credentials (University or research center affiliated), or doctors / HCPs with stated affiliation with medical practices, or experts who are classified as coaches, including fitness coaches, nutritionists not falling in the other two expert categories, etc.
The conversations lead by and shaped by these influencers span a multitude of sub-topics: most of them focused on different use cases or applications of peptides – e.g. for recovery (muscle, wounds, skin), longevity (including biohacking), metabolism and weight management (including weight loss), immunology, gastrointestinal health or neurological health, which could include sleep and even mental health.
Over half of the conversation however is not about specific applications or uses cases: this space covers themes like regulatory, specifically FDA status, compounding, clinical trials, but also access and affordability, dosing, efficacy, discussions around risk and harm and general safety.
Institutional science and clinical innovation
At one end, peptides are framed as foundational to next-generation therapies.
A key example is the discussion around personalised dendritic cell vaccines (e.g. DCVax), where peptides are positioned within highly sophisticated immunotherapy frameworks. These conversations are:
– Led by academics, researchers, and scientific commentators
– Focused on clinical trial outcomes, immune system programming, and therapeutic potential
– Embedded within regulated, evidence-driven discourse
Here, peptides are not framed as products – they are infrastructure for innovation.
Consumer-led optimisation and experimentation
At the other end, a fast-moving and fragmented conversation explores peptides as tools for:
– muscle recovery and performance (e.g. CJC-1295, Ipamorelin)
– longevity and metabolic optimisation
– gut health and tissue repair (e.g. BPC-157)
These narratives are driven by a very different influencer ecosystem of users who position themselves as “Experts”. Our classification model separated these accounts from the verified Experts with academic or clinical credentials, grouping them instead into a category we labelled “Expert/Coaches” (fitness coaches, wellness advocates, self-experimenters, commercial “optimisation” communities).
In this space, peptides are often framed as:
– accessible alternatives to traditional therapies
– part of a broader “biohacking” toolkit
– solutions operating ahead of regulation
The fault line: regulation, risk, and access
Bridging these two worlds is a persistent and highly charged narrative around:
– FDA regulation and enforcement
– compounding pharmacies and access models
– grey- and black-market sourcing
– patient safety and lack of clinical evidence
This is where reputational risk intensifies.
For example:
– Discussions around platforms like Hims & Hers Health illustrate attempts to legitimise peptide access through regulated, doctor-led pathways
– At the same time, clinicians actively warn against premature adoption and unregulated use, particularly in the absence of robust human data
This creates a volatile communications environment where:
– innovation narratives can quickly become risk narratives
– and commercial activity can trigger regulatory scrutiny
Even within high-credibility stakeholders, the conversation is not uniform.
Experts and academics
– Focus on metabolic disease, immunotherapy, and systems-level impact
– Position peptides within long-term clinical and regulatory frameworks
– Emphasise infrastructure, not hype
Healthcare professionals
– Anchor discussions around approved therapies, particularly GLP-1 receptor agonists
– Highlight real-world outcomes and patient safety
– Express caution around:
- off-label use
- longevity protocols
- insufficient evidence
The result is a nuanced but consistent message within academia and HCP influencers:
Peptides represent significant potential – but require rigorous validation, clear governance, and controlled adoption.
What this means for pharma and biotech communicators following peptides:
- You are not looking at a single conversation: You are navigating parallel ecosystems with different rules, audiences, and risk profiles.
- Influence is networked, not linear: Key stakeholders are defined by connectivity and credibility, not just reach.
- Regulatory narratives are central: and are highly politicized, especially in the US.
- Misinformation risk is structurally embedded: Particularly where consumer experimentation outpaces clinical evidence.
Seeing the structure behind the noise
The peptide conversation on X is not just large: it is structurally complex, highly polarised, and strategically significant.
Understanding it requires more than dashboards.
It requires:
– network-level visibility
– stakeholder-level intelligence
– and contextual, human-led interpretation
This is where advanced analytics moves from reporting to strategic advantage, and this is how Commetric helps communications leaders go further: from data to insight, and from insight to confident, business-critical decisions.
Reach out for more information to our Healthcare Insights team at healthcare.insights[at]commetric.com